Protalix (III)

A few months ago I bought Protalix on the rumor that the FDA was about to approve its product, some kind of human protein produced by carrot cells. The FDA demanded more tests and a second review was scheduled in February 2012, so Protalix lost 50% of its value. The platform has immense potential: no one is complaining yet about genetic engineering on plants. Now I read that the Chinese have been following a similar development path, but they are farther from a marketable product. This validates the approach and my investment.